David Hochman General Information
Mr. David Hochman is a Co-Founder & serves as Chief Executive Officer & Chairman at Orchestra BioMed. Mr. David Hochman served as Board Member at Adgero Biopharmaceuticals. He also co-founded Orchestra's predecessors and now wholly-owned subsidiaries, Caliber, BackBeat, and Freehold. Mr. Hochman served as a member of the boards of directors of Caliber, FreeHold, and BackBeat from December 2008, December 2010, and June 2010, respectively, until November 2018. He also served as BackBeat's President from its inception in June 2010 until May 2018. Mr. Hochman has served as Chairman of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company that Orchestra has a strategic holding in, since December 2016, and has served as Chairman of Motus GI's wholly-owned subsidiary, Motus GI Medical Technologies Ltd., since 2011. Mr. Hochman has served as a board observer of Vivasure since 2019. Mr. Hochman has over 25 years of healthcare entrepreneurial, venture capital, and investment banking experience. From 2006 until December 2019, he co-founded and was the Managing Partner of Orchestra Medical Ventures, LLC (OMV), a medical technology venture capital firm. Funds managed by OMV were stockholders of Orchestra prior to their dissolution. From December 2009 to December 2019, he also served as President and a board member of Accelerated Technologies, Inc., a medical device accelerator company managed by OMV that helped create the concepts for BackBeat CNT, Virtue SAB, FreeHold devices, the Pure-Vu system, PerQSeal, and that Orchestra acquired in December 2019. From December 2013 until September 2020, Mr. Hochman was a co-founder and board member of Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a Nasdaq-listed clinical-stage biopharmaceutical company. Prior to co-founding OMV, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies, from 2002 to 2006. He was also Managing Director of private equity firm Spencer Trask Ventures, Inc. from 2000 to 2006, during which time he led financing transactions for over twenty early-stage companies raising over $420.0 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750.0 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a formerly NYSE-listed biopharmaceutical company developing longer-lasting versions of approved therapeutic proteins, which was purchased by Opko Health, Inc. in 2013 for over $600.0 million. He currently serves as President and a board member of the Mollie Parnis Livingston Foundation. He earned a B.A. with honors from the University of Michigan. We believe that Mr. Hochman's role as a co-founder of Orchestra's predecessors and founder of Orchestra, his experience in healthcare innovation and venture capital, his leadership at other companies, including publicly-traded medical technology and biotechnology companies, his financial experience, and his extensive knowledge of our business based on his years as Chief Executive Officer provide him with the qualifications and skills to serve on our board of directors. He serves as Board Observer at Vivasure Medical.